BRIEF-Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy

Reuters06-17

June 17 (Reuters) - Fortress Biotech Inc :

* MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA FROM COMPLETE WALDENSTROM MACROGLOBULINEMIA COHORT OF PHASE 1/2 CLINICAL TRIAL OF MB-106, CD20-TARGETED AUTOLOGOUS CAR-T THERAPY

* MUSTANG BIO INC: OVERALL RESPONSE RATE OF 90% IN COHORT WITH DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE REMISSION AT 31 MONTHS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444525164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444525164","market":"us","top_or_hot":-1,"title":"BRIEF-Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy","media":"Reuters","content":"<html><body><p>June 17 (Reuters) - Fortress Biotech Inc   :</p><p>   * MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA FROM COMPLETE WALDENSTROM MACROGLOBULINEMIA <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PHASE 1/2 CLINICAL TRIAL OF MB-106, CD20-TARGETED AUTOLOGOUS CAR-T THERAPY</p><p>   * MUSTANG BIO INC: OVERALL RESPONSE RATE OF 90% IN COHORT WITH DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE REMISSION AT 31 MONTHS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 17 (Reuters) - Fortress Biotech Inc   :   * MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA FROM COMPLETE WALDENSTROM MACROGLOBULINEMIA COHORT OF PHASE 1/2 CLINICAL TRIAL OF MB-106, CD20...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBIO","symbol_name":"Mustang Bio, Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2444525164","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444525164","pubTimestamp":1718628709,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 17  - Fortress Biotech Inc   :   * MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA FROM COMPLETE WALDENSTROM MACROGLOBULINEMIA COHORT OF PHASE 1/2 CLINICAL TRIAL OF MB-106, CD20-TARGETED AUTOLOGOUS CAR-T THERAPY   * MUSTANG BIO INC: OVERALL RESPONSE RATE OF 90% IN COHORT WITH DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE REMISSION AT 31 MONTHSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBIO":"Mustang Bio, Inc","BK4139":"生物科技","FBIO":"Fortress Biotech Inc."},"translate_title":"简报-野马生物公布MB-106 Car-T疗法1/2期临床试验的有利疗效和安全性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBIO":0.9,"MBIO":0.9},"content_text":"June 17 (Reuters) - Fortress Biotech Inc   :   * MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA FROM COMPLETE WALDENSTROM MACROGLOBULINEMIA COHORT OF PHASE 1/2 CLINICAL TRIAL OF MB-106, CD20-TARGETED AUTOLOGOUS CAR-T THERAPY   * MUSTANG BIO INC: OVERALL RESPONSE RATE OF 90% IN COHORT WITH DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE REMISSION AT 31 MONTHSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444525164"}